Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:03 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clot Dissolving Treatment for Blood Clots in the Lungs
NCT00680628 · Wake Forest University Health Sciences · PHASE3 · terminated · last registry update 2022-10-12 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “PI changed institution and impossible to solve problem with contract's sites” | – | Registry record, Wake Forest University Health Sciences |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PLAT within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-07-28Phase 3 first posted: Ji Xunming,MD,PhD, Intravenous thrombolysis(rt-PA) (NCT05965687)
- 2023-07-28Phase 3 first posted: Ji Xunming,MD,PhD, Intravenous thrombolysis(rt-PA) (NCT05965193)
- 2023-06-06Also stopped (terminated): Life Recovery Systems, Magnesium Sulfate + tPA (NCT02453373)
- 2023-05-12Phase 3 first posted: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Alteplase (NCT05856851)
- 2023-04-26Results posted on the registry: Boehringer Ingelheim, Alteplase (from modified manufacturing process) + Alteplase (from current manufacturing process) (NCT04419493)
- 2023-04-24Phase 3 first posted: The First Affiliated Hospital of University of Science and Technology of China, Intravenous thrombolysis (NCT05827042)
- 2023-04-20Results posted on the registry: Thrombolex, Inc., r-tPA (NCT04248868)
- 2023-04-06Results posted on the registry: Hooman Poor, Tenecteplase + Placebo (NCT04505592)
- 2023-04-04Phase 3 first posted: Hospital Clinic of Barcelona, Intraarterial alteplase (NCT05797792)
- 2023-03-30Results posted on the registry: Thrombolex, Inc., r-tPA (NCT03927508)
- 2023-03-23Also stopped (withdrawn): Universitaire Ziekenhuizen KU Leuven, Intravenous Infusion (NCT03417401)
- 2023-03-13Phase 3 first posted: Chinese University of Hong Kong, Tissue Plasminogen Activator (NCT05766124)
- 2023-02-27Phase 3 first posted: Beijing Tiantan Hospital, Alteplase + Tenecteplase (NCT05745259)
- 2023-01-27Phase 3 first posted: The First Affiliated Hospital of University of Science and Technology of China, Tenecteplase (NCT05701956)
- 2023-01-26Phase 3 first posted: Tasly Biopharmaceuticals Co., Ltd., rhPro-UK + rt-PA (NCT05700591)
- 2023-01-13Phase 3 first posted: The First Affiliated Hospital of University of Science and Technology of China, Tenecteplase (NCT05684172)
- 2022-12-20Phase 3 first posted: General Hospital of Shenyang Military Region, Tenecteplase (NCT05657457)
- 2022-12-20Phase 3 first posted: General Hospital of Shenyang Military Region, Tenecteplase (NCT05657470)
- 2022-12-20Phase 3 first posted: General Hospital of Shenyang Military Region, Tenecteplase (NCT05657444)
- 2022-12-02Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Intravenous thrombolysis agents (NCT05634382)
- 2022-11-25Phase 3 first posted: Hospital Universitari Vall d'Hebron Research Institute, Tenecteplase (NCT05626972)
- 2022-11-23Results posted on the registry: Hospital for Special Surgery, New York, E-Aminocaproic acid (NCT02257580)
- 2022-11-01Phase 3 first posted: AO GENERIUM, GNR-060 + Metalyse (NCT05601999)
- 2022-08-12Phase 3 first posted: Insel Gruppe AG, University Hospital Bern, Tenecteplase (NCT05499832)
- 2022-08-02Phase 3 first posted: ZZ Biotech, LLC, 3K3A-APC (NCT05484154)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision